An interventional study of Serial Biopsy in Inflammatory Bowel Diseases, sponsored by Terrence A Barrett. Completed at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Terrence A Barrett · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.
Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 230th largest by enrollment of the 327 interventional ones that give a count, is one of 24 that started in 2021, is one of 131 with no phase, and was the 315th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–80
Stanford University · Sites in United States
Ages 18+
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
Palisade Bio · Sites in United States, Canada, Czechia and 9 more countries
Ages 18–75
Eli Lilly and Company · Sites in United States, Canada, Denmark and 4 more countries
Ages 3 wk+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
463 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 59 · Phase 2 83 · Phase 3 46 · Phase 4 31
First in 1995; this study’s year is marked. 24 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 50 across the 327 interventional studies, 134 across the 132 observational. Of the 301 that completed or were terminated, 120 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
132 of 463 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Terrence A Barrett as lead sponsor.
Terrence A Barrett has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
43 of the studies in Inflammatory Bowel Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT06188793University of MichiganVirtual Reality (VR) -Directed Brain Gut Behavioral Treatment (BGBT) for Inflammatory Bowel Disease (IBD) Inpatients | 2026-12 |
| NCT04508088Massachusetts General HospitalSkeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease | 2026-12 |
| NCT07769437University Hospitals Cleveland Medical CenterNon-nutritive Sweeteners in Inflammatory Bowel Disease | 2026-12 |
Add all 43 to your calendar (.ics) → With an account.
Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the current study is to compare non-healing colonic ulcers in patients with inflammatory bowel disease (IBD) with iatrogenic colonic ulcers (biopsy sites) in healthy control patients and patients with rheumatoid or psoriatic arthritis. Patients will be biopsied at baseline and again at a follow-up visit in a "biopsy of the biopsy" approach. These biopsies will be used to reveal patterns about gene expression and mitochondrial function during ulcer healing.
Induction of mucosal healing in inflammatory bowel disease (IBD) is associated with reduced hospitalizations, surgeries, and reduced cancer risk. However, previous studies have shown that 54-69% of ulcerative colitis (UC) patients fail to heal ulcers after several weeks of treatment, and roughly half do not maintain remission at one year. The single most important factor in preventing severe medical consequences, like colon removal surgery or cancer, is treatment to completely heal the top layer of the intestine as quickly as possible. Healing is a complex process and the dysfunction observed in colitis can only be fully understood by comparison to healing in non-IBD patients.
This is a prospective trial involving three groups of patients: 1) IBD patients with active disease, newly treated with anti-TNF therapy (biologic failure or naïve); 2) non-IBD patients with rheumatoid/psoriatic arthritis who are receiving anti-TNF therapy, and 3) healthy control patients. Biopsies will be collected at baseline during standard of care endoscopy and at a follow-up research endoscopy.
This study will probe mechanisms of ulcer healing by analyzing gene expression patterns and mitochondrial function.
Inclusion Criteria (Group 1):
Inclusion Criteria (Group 2):
Inclusion Criteria (Group 3):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will be healthy (not diagnosed with inflammatory bowel disease).
Procedure: Serial Biopsy
Participants in this group will have been diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) and have either failed treatment with biologics or be naive to biologic therapy.
Procedure: Serial Biopsy
Participants in this group will have been diagnosed with rheumatoid (RA) or psoriatic arthritis (PsA) and will be receiving anti-TNF antibody therapy at the time of enrollment.
Procedure: Serial Biopsy
During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed. Patients will return for a follow-up colonoscopy 4-35 days later. An additional 16-20 biopsies will be collected in a "biopsy of the biopsy" approach.
Change in Relative Ratio of Mitochondrial DNA to Nuclear DNA
Change in relative ratio of mitochondrial DNA to nuclear DNA in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.
Time frame: 35 days
Fold Change in Expression Levels of cMyc
Fold change in expression levels of cMyc (mRNA) will be measured in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.
Time frame: Baseline and 35 days
Fold Change in Expression Levels of PGC-1 Alpha
Fold change in expression of PGC-1 alpha (mRNA) will be measured in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.
Time frame: Baseline and 35 days
Change in Expression Levels of Ki67
Change in Ki67 alpha (mRNA) expression will be measured by immunohistochemistry in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.
Time frame: 35 days
Number of Visible Ulcers
The number of visible ulcers will be assessed during the follow-up endoscopy for healthy patients and rheumatoid/psoriatic arthritis patients only.
Time frame: 1 day (at follow-up visit)
Change in Full Mayo Score
Change in Full Mayo Score, a measure of inflammatory bowel disease activity, from baseline to 35 days. The Full Mayo Score ranges from 0-12, with higher scores indicating worse disease activity. The score is calculated by summing the four components of the Mayo Score: stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment.
Time frame: Baseline and 35 days
Change in Segmental SES-CD Score
The Simple Endoscopic Score (SES) will be calculated at baseline and follow-up in patients with Crohn's disease (CD) only. The SES-CD score incorporates ulcer size, narrowing, and the area affected by disease or ulceration. Scores range from 0-12; lower scores indicate remission while higher scores indicate severe endoscopic activity.
Time frame: 35 days
Fecal Calprotectin Levels
Levels of fecal calprotectin (ug/g) will be measured from stool samples collected from patients at any time during the study protocol.
Time frame: 35 days
No participants were able to be enrolled in the Rheumatoid/Psoriatic Arthritis Arm.
| Milestone | Healthy Controls | Inflammatory Bowel Disease | Rheumatoid/Psoriatic Arthritis |
|---|---|---|---|
| Started | 15 | 11 | 0 |
| Completed | 10 | 11 | 0 |
| Not completed | 5 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: No sample collected | 1 | 0 | 0 |
Change in relative ratio of mitochondrial DNA to nuclear DNA in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.
| Relative Ratio of mtDNA to nucDNA | Healthy Controls | Inflammatory Bowel Disease | Rheumatoid/Psoriatic Arthritis |
|---|---|---|---|
| Change in Relative Ratio of Mitochondrial DNA to Nuclear DNA | 1218.374 ± 148.83 | 394.98 ± 39.22 | — |
Fold change in expression levels of cMyc (mRNA) will be measured in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.
| Relative Fold Change | Healthy Controls | Inflammatory Bowel Disease | Rheumatoid/Psoriatic Arthritis |
|---|---|---|---|
| Fold Change in Expression Levels of cMyc | 2.41 ± 0.24 | 1.09 ± 0.225 | — |
Fold change in expression of PGC-1 alpha (mRNA) will be measured in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.
| Relative Fold Change | Healthy Controls | Inflammatory Bowel Disease | Rheumatoid/Psoriatic Arthritis |
|---|---|---|---|
| Fold Change in Expression Levels of PGC-1 Alpha | 0.96 ± 0.02 | 0.315 ± 0.05 | — |
Change in Ki67 alpha (mRNA) expression will be measured by immunohistochemistry in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.
| Ki67+Cells/Crypt | Healthy Controls | Inflammatory Bowel Disease | Rheumatoid/Psoriatic Arthritis |
|---|---|---|---|
| Change in Expression Levels of Ki67 | 35.8 ± 2.878 | 17 ± 0.997 | — |
The number of visible ulcers will be assessed during the follow-up endoscopy for healthy patients and rheumatoid/psoriatic arthritis patients only.
No measurements were reported for this outcome.
Change in Full Mayo Score, a measure of inflammatory bowel disease activity, from baseline to 35 days. The Full Mayo Score ranges from 0-12, with higher scores indicating worse disease activity. The score is calculated by summing the four components of the Mayo Score: stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment.
| score on a scale | Healthy Controls | Inflammatory Bowel Disease | Rheumatoid/Psoriatic Arthritis |
|---|---|---|---|
| Change in Full Mayo Score | — | 5 ± 0.726 | — |
The Simple Endoscopic Score (SES) will be calculated at baseline and follow-up in patients with Crohn's disease (CD) only. The SES-CD score incorporates ulcer size, narrowing, and the area affected by disease or ulceration. Scores range from 0-12; lower scores indicate remission while higher scores indicate severe endoscopic activity.
| score on a scale | Healthy Controls | Inflammatory Bowel Disease | Rheumatoid/Psoriatic Arthritis |
|---|---|---|---|
| Change in Segmental SES-CD Score | — | 8.2 ± 2.28 | — |
Levels of fecal calprotectin (ug/g) will be measured from stool samples collected from patients at any time during the study protocol.
| ug/Kg | Healthy Controls | Inflammatory Bowel Disease | Rheumatoid/Psoriatic Arthritis |
|---|---|---|---|
| Fecal Calprotectin Levels | 151.2 ± 31.93 | 1203.57 ± 305.898 | — |
Collected over 30 Days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy Controls | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Inflammatory Bowel Disease | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| Rheumatoid/Psoriatic Arthritis | — | — | — |
No participants were able to be enrolled in the Rheumatoid/Psoriatic Arthritis Arm.
| Age, Continuous(years) | Healthy Controls | Inflammatory Bowel Disease | Rheumatoid/Psoriatic Arthritis | Total |
|---|---|---|---|---|
| Mean | 52.44 ± 13.398 | 36.7 ± 6.815 | — | 44.57 ± 11.13 |
| Sex: Female, Male(Participants) | Healthy Controls | Inflammatory Bowel Disease | Rheumatoid/Psoriatic Arthritis | Total |
|---|---|---|---|---|
| Female | 8 | 5 | — | 13 |
| Male | 7 | 6 | — | 13 |
| Ethnicity (NIH/OMB)(Participants) | Healthy Controls | Inflammatory Bowel Disease | Rheumatoid/Psoriatic Arthritis | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | — | 1 |
| Not Hispanic or Latino | 15 | 10 | — | 25 |
| Unknown or Not Reported | 0 | 0 | — | 0 |
| Race (NIH/OMB)(Participants) | Healthy Controls | Inflammatory Bowel Disease | Rheumatoid/Psoriatic Arthritis | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | — | 0 |
| Asian | 0 | 0 | — | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | — | 0 |
| Black or African American | 2 | 1 | — | 3 |
| White | 13 | 9 | — | 22 |
| More than one race | 0 | 0 | — | 0 |
| Unknown or Not Reported | 0 | 1 | — | 1 |
| Region of Enrollment(participants) | Healthy Controls | Inflammatory Bowel Disease | Rheumatoid/Psoriatic Arthritis | Total |
|---|---|---|---|---|
| United States | 15 | 11 | — | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Aug 2024, 39 months.
Results were first posted in Sep 2026, 2 years 1 month after primary completion.
Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 39 months is above that.
Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jun 2026 → Aug 2024 and completion Jun 2026 → Aug 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.